{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T21:47:53Z","timestamp":1787089673672,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ijtb.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T02:34:58Z","timestamp":1551234898000},"page":"209-213","source":"Crossref","is-referenced-by-count":16,"title":["Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India"],"prefix":"10.1016","volume":"66","author":[{"given":"Rohit","family":"Sarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Vohra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Munjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.K.","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Myneedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoy","family":"Kumar Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.K.","family":"Mathuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2019.02.009_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/230240bc-bcf3-46b2-9b21-2e6e584f7333","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijtb.2019.02.009_bib2","series-title":"The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis Interim Policy Guidance","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.ijtb.2019.02.009_bib3","series-title":"Bedaquiline (Sirturo): Summary of Product Characteristics London","year":"2015"},{"issue":"2","key":"10.1016\/j.ijtb.2019.02.009_bib4","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.4081\/idr.2016.6569","article-title":"New antituberculosis drugs: from clinical trial to programmatic use","volume":"8","author":"Gualano","year":"2016","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.ijtb.2019.02.009_bib5","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fmicb.2017.02452","article-title":"Repurposing and revival of the drugs: a new approach to combat the drug resistant tuberculosis","volume":"8","author":"Sharma","year":"2017","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.ijtb.2019.02.009_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/s1806-37562017000000436","article-title":"New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis","volume":"44","author":"Silva","year":"2018","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.ijtb.2019.02.009_bib7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"Zignol","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijtb.2019.02.009_bib8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.5588\/ijtld.14.0944","article-title":"Treatment of drug- resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis","volume":"19","author":"Ndjeka","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.02.009_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijtb.2019.02.009_bib10","series-title":"Global Tuberculosis Report, 2016","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.ijtb.2019.02.009_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5588\/ijtld.15.0962","article-title":"Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study","volume":"20","author":"Bonnet","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijtb.2019.02.009_bib12","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2019.02.009_bib13","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR- TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2019.02.009_bib14","series-title":"About the endTB Project","author":"endTB","year":"2017"},{"key":"10.1016\/j.ijtb.2019.02.009_bib15","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570719300757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570719300757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:50:44Z","timestamp":1553043044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570719300757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0019570719300757"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2019.02.009","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}